10-K: Teva's 2025 Revenue Climbs 4% Amid Strategic Pivot

Teva Pharmaceutical Industries Limited reported a 4% increase in 2025 revenues, driven by strong performance in key innovative products and strategic pipeline advancements, despite declines in certain generic markets.

Summary

• Total revenues for 2025 reached $17,258 million, a 4% increase in U.S. dollars (3% in local currency) compared to 2024.
• The United States segment saw revenues increase by 14% to $9,186 million and profit by 46% to $3,356 million in 2025.
• Europe segment revenues decreased by 1% to $5,040 million (5% in local currency), with profit down 17% to $1,303 million.
• International Markets segment revenues decreased by 12% to $2,162 million (11% in local currency), with profit down 24% to $336 million, primarily due to the divestment of the Japan business venture.
• Gross profit margin improved to 51.8% in 2025 from 48.7% in 2024, mainly due to a favorable product mix and milestone payments.
• Operating income was $2,157 million in 2025, a significant improvement from an operating loss of $303 million in 2024.
• Net income attributable to Teva was $1,410 million in 2025, compared to a net loss of $1,639 million in 2024.
• Diluted earnings per share (EPS) was $1.21 in 2025, a turnaround from a diluted loss per share of $1.45 in 2024.
• Total debt decreased to $16,807 million as of December 31, 2025, from $17,783 million as of December 31, 2024.
• Cash flow generated from operating activities increased to $1,649 million in 2025 from $1,247 million in 2024.
• Free cash flow generated was $2,396 million in 2025, up from $2,068 million in 2024.
• R&D expenses, net, increased slightly by 2% to $1,013 million in 2025, reflecting continued investment in the Pivot to Growth strategy.
• Legal settlements and loss contingencies expenses decreased to $467 million in 2025 from $761 million in 2024.
• The company recorded a $726 million impairment charge related to a manufacturing facility in Europe in 2025.
• Teva's Pivot to Growth strategy is in its 'Accelerate Growth' phase, focusing on innovative portfolio expansion, capital allocation, and organizational modernization.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to the significant turnaround in net income and operating profit, strong growth in key innovative products, and substantial debt reduction. However, ongoing challenges in generic markets and a complex legal/regulatory landscape temper the overall sentiment.

Positives

• Strong revenue growth from key innovative products: AUSTEDO (35% increase to $2,217 million), AJOVY (42% increase to $295 million in US, 25% in Europe), and UZEDY (63% increase to $191 million).
• Received $500 million in development milestone payments in Q4 2025 for duvakitug (anti-TL1A) upon initiation of Phase 3 studies.
• Successful launches of biosimilars SELARSDI (ustekinumab-aekn) and EPYSQLI (eculizumab-aagh) in the U.S. in 2025.
• Significant reduction in total debt by $976 million, from $17,783 million in 2024 to $16,807 million in 2025.
• Operating income improved substantially to $2,157 million in 2025 from an operating loss of $303 million in 2024.
• Net income attributable to Teva turned positive at $1,410 million in 2025, compared to a net loss of $1,639 million in 2024.
• Cash flow from operating activities increased by $402 million to $1,649 million in 2025.
• Free cash flow increased to $2,396 million in 2025, demonstrating improved liquidity.
• Submitted a New Drug Application (NDA) for olanzapine LAI (TEV-749) in December 2025, based on positive Phase 3 trial results.
• Emrusolmin (TEV-286) received U.S. FDA Fast Track designation for Multiple System Atrophy (MSA).
• Received EMA approvals for biosimilars PONLIMSI (denosumab) and DEGEVMA (denosumab) in November 2025.
• Successfully settled the nationwide opioid litigation, with payments spread over 13 years, reducing future uncertainty.
• Resolved DOJ Civil Division allegations with a $25 million settlement, including no admission of wrongdoing.

Negatives

• Revenues in the Europe segment decreased by 1% (5% in local currency) and profit decreased by 17% in 2025.
• Revenues in the International Markets segment decreased by 12% (11% in local currency) and profit decreased by 24% in 2025, primarily due to the divestment of the Japan business venture.
• Lower proceeds from the sale of certain product rights contributed to revenue declines in Europe and International Markets.
• Generic product revenues in Europe decreased in local currency terms due to lower volumes and price reductions.
• COPAXONE revenues continued to decline in Europe (15% decrease) and International Markets (34% decrease) due to alternative therapies and competition.
• Anda's revenues decreased by 3% in 2025 due to lower volumes.
• Recorded a $726 million impairment charge related to a manufacturing facility in Europe in 2025.
• Goodwill impairment charge of $1,280 million was recorded in 2024 related to the Teva API reporting unit.
• Ongoing macroeconomic headwinds, including fluctuating foreign exchange rates and supply chain disruptions, continue to pose risks.
• The U.S. District Court for the District of Columbia granted CMS's motion for summary judgment in Teva's lawsuit against the IRA's Drug Price Negotiation Program, which Teva is appealing.

Risks

• Substantial dependence on generic products, which face intense price erosion and competition from other manufacturers and authorized generics.
• Concentration of the customer base and commercial alliances among customers may increase pricing pressures.
• Delays in launches of new generic products could adversely affect sales and profitability.
• Intense competition for innovative medicines from numerous pharmaceutical and biotechnology companies, potentially leading to product obsolescence or price reductions.
• Significant indebtedness requires substantial interest and principal payments, limiting financial flexibility and potentially requiring additional funds on unfavorable terms.
• Global economic conditions, including inflation, fluctuating foreign exchange rates, and supply chain disruptions, can increase operating costs and impact financial results.
• Significant disruptions of information technology systems, including cybersecurity attacks and risks related to AI adoption, could adversely affect business operations and data security.
• Complexity of product manufacturing and reliance on single sources for raw materials could lead to supply chain interruptions.
• Geopolitical instability, such as ongoing conflicts in Russia/Ukraine and the Middle East, exposes the company to risks in sales, supply chain, and operational costs.
• Inability to attract, hire, integrate, and retain highly skilled key personnel, especially in a competitive industry.
• Challenges in successfully bidding for or integrating future acquisitions and licensing opportunities.
• Failure to successfully and cost-effectively consummate planned divestitures, such as the API business, could adversely affect growth opportunities.
• Failure to comply with complex legal and regulatory requirements (FDA, EMA, pricing laws, competition laws, anti-bribery laws, privacy laws) could result in fines, penalties, and reputational harm.
• Healthcare reforms, including the Inflation Reduction Act (IRA) and Most-Favored-Nation pricing initiatives, could lead to greater pricing pressures and reduced reimbursement.
• Ongoing public concern over opioid abuse and related legal/regulatory actions, including remaining third-party payer lawsuits, could result in large monetary penalties.
• Increased government scrutiny from competition and pricing authorities worldwide may expose the company to significant damages and commercial restrictions.
• Third parties may claim patent infringement, potentially leading to substantial liability for damages if products are sold prior to final court decisions.
• Susceptibility to significant product liability claims not fully covered by insurance, particularly with new innovative medicines.
• Potential significant increases in tax liabilities due to audits, changes in tax legislation (e.g., Pillar Two taxation), or changes in business operations.
• Failure to maintain effective internal control over financial reporting could adversely affect financial reporting accuracy and timeliness.

Future Outlook

Teva expects continued growth from its key innovative medicines (AUSTEDO, AJOVY, UZEDY) and plans to expand its innovative and biosimilar pipeline through internal efforts and strategic opportunities. The company anticipates ongoing competition and pricing pressure in generic markets but sees opportunities in new drug applications and complex products. Macroeconomic headwinds, including supply chain disruptions and exchange rate fluctuations, are expected to continue impacting operations. Teva will continue its Teva Transformation programs to achieve cost savings through operational efficiencies and headcount reduction, maintain financial discipline, and pursue debt repayment. The company also aims for continued improvement in credit ratings.

Management Comments

• Management is committed to integrating artificial intelligence (AI) technologies to optimize internal processes, strengthen risk management, and support product R&D.
• The company is actively transforming and modernizing its business through Teva Transformation programs, expected to generate ~$700 million of net savings through 2027.
• Management believes the company has one of the most extensive pipelines of generic products in the industry, with a focus on high-value and complex formulations.
• The company is working diligently across its supply chain to ensure continuous and stable supply amidst medicine shortages.

Industry Context

StockSavvy.ai notes that Teva's performance reflects broader pharmaceutical industry trends, including the increasing importance of innovative and biosimilar pipelines for growth, as generic markets face intense price erosion. The focus on AI integration aligns with industry-wide efforts to enhance R&D, manufacturing, and operational efficiency. The ongoing legal and regulatory scrutiny, particularly regarding drug pricing and opioid litigation, highlights the challenging external environment for pharmaceutical companies. The divestiture of non-core assets like the API business is a common strategy for companies seeking to streamline operations and focus capital on high-growth areas.

Corporate Governance

Legal Proceedings

• Ongoing patent infringement litigation with GlaxoSmithKline (GSK) regarding carvedilol tablets, with Teva appealing a decision that reversed a $176.5 million jury verdict in its favor.
• Ongoing patent litigation with Vanda Pharmaceuticals related to Hetlioz, with a second case pending in U.S. District Court for the District of Delaware and trial set for August 3, 2026.
• Antitrust litigation regarding extended-release venlafaxine (generic Effexor XR) with a settlement approved for indirect purchaser plaintiffs, while litigation continues with other plaintiffs.
• Antitrust litigation regarding lamotrigine (generic Lamictal) with ongoing discovery for newly added individual plaintiffs.
• Multidistrict antitrust litigation regarding Niaspan (extended-release niacin) with the denial of indirect purchasers' class certification affirmed, and litigation ongoing.
• Antitrust investigation by the European Commission into COPAXONE, resulting in a 462.6 million euros fine in October 2024, which Teva appealed in January 2025; Teva provided surety guarantees.
• Antitrust lawsuits by Mylan Pharmaceuticals and purported purchasers against Teva regarding COPAXONE, consolidated in the U.S. District Court for the District of New Jersey.
• Antitrust litigation in the U.K. Competition and Markets Authority (CMA) regarding hydrocortisone tablets, with appeals pending on certain issues.
• Antitrust class action complaints in the U.S. District Court for the District of New Jersey against Teva and Natco Pharma Limited regarding Revlimid (lenalidomide) settlements, with motions to dismiss pending.
• Antitrust complaints in the U.S. District Court for the District of Kansas against Teva, Cephalon, and a former executive related to EpiPen (epinephrine injection) and NUVIGIL (armodafinil), with claims limited to NUVIGIL.
• Putative class action complaints in the U.S. District Court for the District of Massachusetts against Teva alleging anticompetitive conduct to suppress generic competition to QVAR asthma inhalers; a settlement in principle has been reached.
• Antitrust lawsuits in the U.S. District Court for the District of Rhode Island against Bausch Health Companies Inc., Teva, and others regarding the Xifaxan (rifaximin) settlement, with some plaintiff groups voluntarily dismissing claims.
• Government investigations and litigation relating to pricing and marketing, including a 3-year deferred prosecution agreement (DPA) with the DOJ for criminal felony Sherman Act violations, requiring a $225 million fine and divestiture of pravastatin.
• Settlement agreement with the DOJ Civil Division for $25 million to resolve allegations of market allocation and/or price-fixing, paid in Q4 2024 and January 2026.
• Ongoing civil actions by attorneys general of various states and private plaintiffs alleging conspiracies to fix prices and/or allocate market share of generic products, with some settlements reached and others pending.
• Nationwide settlement agreement finalized in June 2023 to resolve claims related to opioid sales and distribution, requiring payments of up to $4.25 billion (including product supply) over 13 years.
• Ongoing product liability litigation related to nitrosamine impurities in valsartan, losartan, metformin, and ranitidine products, with MDLs pending and some claims dismissed or settled.
• Product liability actions involving Paragard (IUD) consolidated in the U.S. District Court for the Northern District of Georgia, with a bellwether trial commenced in January 2026.
• Civil subpoena from the U.S. Attorneys office in Boston, Massachusetts, requesting documents related to the sale and marketing of AUSTEDO and risperidone LAI.
• Civil investigative demand from the Federal Trade Commission (FTC) seeking documents and information related to patents listed in the Orange Book for certain inhaler products.
• Civil investigative demand from the U.S. Attorneys office in Boston, Massachusetts, and the Civil Division of the Department of Justice requesting documents related to manufacturing practices at its former Irvine, California, facility.
• Lawsuit filed against Eli Lilly & Co. for alleged patent infringement related to galcanezumab product for migraine, with Teva appealing a reversed jury verdict.
• Lawsuit filed against Amarin Pharma, Inc. alleging a scheme to stifle generic competition to Vascepa (icosapent ethyl), with motions pending.
• Lawsuit filed against Corcept Therapeutics, Inc. and Optime Care Inc. alleging a scheme to stifle generic competition to Korlym (mifepristone), with motions pending.

Stakeholder Impact

• Shareholders: Positive impact from increased net income and EPS, debt reduction, and strategic focus on growth engines. Potential dilution from future capital raises. Share price influenced by financial performance, strategic updates, and litigation outcomes.
• Employees: Impacted by Teva Transformation programs, including headcount reduction (approximately 8% of workforce by end of 2027). Focus on employee wellbeing, career growth, training, and development programs.
• Customers: Benefit from new innovative and biosimilar product launches. Affected by pricing pressures in generic markets and potential supply chain disruptions.
• Suppliers: Subject to ongoing credit evaluations and potential changes in payment terms. API business divestiture could impact API suppliers.
• Creditors: Benefit from debt reduction and improved financial leverage. Sustainability-linked bonds tie interest rates/premiums to sustainability performance targets.

Next Steps

• Continue to execute on the four key pillars of the Pivot to Growth strategy, focusing on accelerating growth, stepping up innovation, sustaining the generics business, and focusing the business to accelerate growth.
• Renewed sales process for the API business divestiture.
• Continue Phase 3 programs for duvakitug (anti-TL1A) in ulcerative colitis and Crohn's disease.
• Continue Phase 3 trial for DARIs (Dual-action Asthma Rescue Inhaler) in adult and pediatric populations.
• Advance development of anti-IL-15 antibody (TEV-408) with a Phase 2b study expected to begin in 2026.
• Monitor and adapt to evolving macroeconomic headwinds, including inflation, interest rates, foreign exchange rates, and supply chain disruptions.
• Continue to implement Teva Transformation programs to achieve expected cost savings through efficiency improvements and headcount reduction.
• Appeal the U.S. District Court's decision regarding the IRA's Drug Price Negotiation Program.
• Continue to defend against remaining opioid-related lawsuits and other antitrust claims.
• Monitor and comply with new and evolving sustainability-related regulatory disclosure regulations (e.g., California Climate Corporate Data Accountability Act, EU CSRD).

Key Dates

Recommendation

Teva's 2025 performance shows a significant turnaround with positive net income, increased operating profit, and substantial debt reduction, driven by strong growth in key innovative products. The strategic pivot towards biopharmaceuticals and a focused generics pipeline is promising. However, the company faces persistent challenges from intense generic competition, ongoing macroeconomic headwinds, and a complex landscape of legal and regulatory proceedings, including significant antitrust and product liability litigations. While the financial improvements are notable, the inherent risks and uncertainties in the pharmaceutical industry, particularly around patent challenges and regulatory changes, suggest a 'hold' recommendation for a seasoned investor, allowing for further observation of sustained growth and resolution of outstanding legal matters.

Keywords

Pharmaceuticals, Generics, Innovative Medicines, Biosimilars, Teva, SEC Filing, 10-K, Financial Results, Debt Reduction, AUSTEDO, AJOVY, UZEDY, duvakitug, Pipeline, R&D, Strategic Pivot, Opioids Litigation, Antitrust, Healthcare Regulation, Supply Chain, Cybersecurity, AI, Intellectual Property